News

Subject to final issuance by the US Patent and Trademark Office, the newly allowed claims will have a July 2016 expiration date. Gerald Proehl, president and CEO of

Teva is currently involved in patent litigation concerning this product in the US District Court of Indiana. A trial date has not been set.

The company sold 4.03 million shares of its common stock at $1.32 per share, and warrants to purchase up to 2.01 million shares of its common stock for

The 12 week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80mg given once or three times daily is effective in

Under the terms of the agreement, Garden State Nutritionals (GSN) will manufacture and deliver a powerful and proprietary anti-aging, antioxidant nutritional supplement for the company. The company will

Results from in vivo human tumor models in mice demonstrated significant inhibition of tumor growth in a broad range of cancer types. In c-Met driven gastric cancer and

Funding from the financing will allow for the initiation of Phase III studies of Paratek’s broad-spectrum antibiotic, PTK 0796, which is being developed to treat serious, often life-threatening

The Phase II trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with measurable advanced or metastatic non-small cell lung cancer who have previously received only

This office is expected to grow rapidly under the leadership of Dr Kornilov and will be primarily focused on supporting the company’s Global Clinical Development brand. Armand Czaplinski,